125 related articles for article (PubMed ID: 21949036)
1. Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial.
Gomes M; Ramacciotti E; Henriques AC; Araujo GR; Szultan LA; Miranda F; Thethi I
Clin Appl Thromb Hemost; 2011; 17(6):633-9. PubMed ID: 21949036
[TBL] [Abstract][Full Text] [Related]
2. Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis.
Casella IB; Puech-Leão P
Rev Assoc Med Bras (1992); 2015; 61(1):44-50. PubMed ID: 25909208
[TBL] [Abstract][Full Text] [Related]
3. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of a Biosimilar Versus Branded Enoxaparin in the Prevention of Venous Thromboembolism Following Major Abdominal Surgery: A Randomized, Prospective, Single-Blinded, Multicenter Clinical Trial.
Ramacciotti E; Ferreira U; Costa AJV; Raymundo SRO; Correa JA; Neto SG; Osvaldt AB; Agati L; Aguiar VCR; Davila R; Caltabiano TB; Magella FM; Volpiani GG; Castelli V; Caffaro RA; DalAcqua LZ; Matheus WE; Sato DY; Russeff GJDS; de Souza DG; Pazetto LE; de Lima TAM; Colnago EMDS; Fugii EY; Mussalem JS; Assao VT; Toffoletto O; Rodrigues DG; Afiune JB; Araujo GR
Clin Appl Thromb Hemost; 2018 Nov; 24(8):1208-1215. PubMed ID: 30021463
[TBL] [Abstract][Full Text] [Related]
5. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
6. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
8. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
9. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
13. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis.
Bottaro FJ; Elizondo MC; Doti C; Bruetman JE; Perez Moreno PD; Bullorsky EO; Ceresetto JM
Thromb Haemost; 2008 Jun; 99(6):1104-11. PubMed ID: 18521515
[TBL] [Abstract][Full Text] [Related]
16. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
[TBL] [Abstract][Full Text] [Related]
17. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin.
Nilsson PE; Bergqvist D; Benoni G; Björgell O; Fredin H; Hedlund U; Nicolas S; Nylander G
Orthopedics; 1997 Feb; 20 Suppl():22-5. PubMed ID: 9048404
[TBL] [Abstract][Full Text] [Related]
18. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial.
Kakkar AK; Agnelli G; Fisher W; George D; Lassen MR; Mismetti P; Mouret P; Murphy J; Lawson F; Turpie AG;
Ann Surg; 2014 Jun; 259(6):1073-9. PubMed ID: 24374549
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery.
Bergqvist D
Br J Surg; 2004 Aug; 91(8):965-74. PubMed ID: 15286956
[TBL] [Abstract][Full Text] [Related]
20. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
